Shaking up China's PD-(L)1 reimbursement landscape, Innovent, Eli Lilly earn coveted spot on national coverage
Innovent and Eli Lilly have claimed the first-ever spot for a PD-(L)1 inhibitor on China’s National Reimbursement Drug List — at a steep discount price that could alter the market landscape for every other checkpoint drug in the country.
Starting in 2020, Tyvyt will be available for RMB2843 ($403) per 100mg, down about 64% from its original price of RMB7838/100mg ($1117.96).
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,700+ biopharma pros reading Endpoints daily — and it's free.